Author:
McCabe C.,Bergmann L.,Bosanquet N.,Ellis M.,Enzmann H.,von Euler M.,Jönsson B.,Kallen K.-J.,Newling D.,Nüssler V.,Paschen B.,de Wilde R.,Wilking N.,Teale C.,Zwierzina H.
Reference49 articles.
1. Pharmacoeconomics behind next-generation oncology drug development;Zwierzina;Eur J Cancer Suppl,2007
2. Fourth hurdle reviews’, NICE, and database applications;Paul;Pharmacoepidemiol Drug Saf,2001
3. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle;Taylor;BMJ,2004
4. US Food and Drug Administration, Center for Biologics Evaluation and ResearchFrequently Asked Questions: What is a Biological Product? www.fda.gov/Cber/faq.htm#3 (25 April 2008, date last accessed)
5. Phase II study of rituximab plus fludarabine in patients with low grade lymphoma: final report;Czuczman;Blood,2001
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献